Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Fineline Cube Apr 27, 2026
Company Drug

Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant

Fineline Cube Apr 27, 2026
Company

La Prairie Holistic Health’s Functional Nutrient Product Approved in Hainan Pilot Zone

Fineline Cube Apr 18, 2025

Switzerland-based Clinique La Prairie Holistic Health SA has received approval for its functional nutrient product...

Company Drug

GSK’s Arexvy RSV Vaccine Receives Favorable ACIP Vote for Adults Aged 50-59

Fineline Cube Apr 18, 2025

UK-based pharmaceutical major GlaxoSmithKline (GSK, NYSE: GSK) has announced a favorable vote from the US...

Company Drug

Gene Cradle Gains NMPA Approval for Phase III Trial of GC101 in Type II 5q Spinal Muscular Atrophy

Fineline Cube Apr 18, 2025

China-based Gene Cradle has received approval from the National Medical Products Administration (NMPA) to proceed...

Company Medical Device

Medtronic’s Implantable Defibrillator System Gains NMPA Approval in China

Fineline Cube Apr 18, 2025

China’s National Medical Products Administration (NMPA) has approved Medtronic’s (NYSE: MDT) endovascular implantable defibrillation electrode...

Company Drug

Zhaoke Ophthalmology Enrolls First Patient for Cyclosporine A Eye Gel Phase III Study

Fineline Cube Apr 18, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the first patient enrollment in a Phase...

Company Deals

Illumina and Tempus AI Collaborate to Advance Next-Generation Sequencing in Clinical Practice

Fineline Cube Apr 18, 2025

US major Illumina (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM) are joining forces to...

Company Deals Medical Device

Junion Therapeutics Secures RMB 100 Million Series A Financing for Weight Loss Device

Fineline Cube Apr 18, 2025

China-based Junion Therapeutics (Xiamen) Co., Ltd has reportedly secured RMB 100 million (USD 13.7 million)...

Company Deals Drug

Eli Lilly Collaborates with BigHat Biosciences to Engineer Advanced Therapeutic Antibodies

Fineline Cube Apr 18, 2025

US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has entered into a collaboration with...

Company Drug

Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer

Fineline Cube Apr 18, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a...

Company Drug

GSK’s Blenrep Approved by UK MHRA for Multiple Myeloma Treatment

Fineline Cube Apr 18, 2025

UK-based pharmaceutical giant UK-based pharmaceutical company GlaxoSmithKline (GSK, NYSE: GSK) has announced the receipt of...

Company Drug

Salubris Pharma’s YOLT-101 Gene Editing Drug Accepted for NMPA Review

Fineline Cube Apr 18, 2025

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced that the National Medical Products Administration...

Company Drug

Hansoh’s HS-20093 ADC Earns BTD for Advanced NSCLC from China’s NMPA

Fineline Cube Apr 18, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that China’s National Medical Products...

Company Deals Drug

Akeso Biopharma Partners with Virogin to Test Ivonescimab and VG201 in Colorectal Cancer Trial

Fineline Cube Apr 17, 2025

China-based Akeso Biopharma (HKG: 9926) has entered into a clinical collaboration with Virogin Biotech Co.,...

Company Drug

Chengdu Kanghong Gains NMPA Approval for KH815 in Advanced Solid Tumors

Fineline Cube Apr 17, 2025

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) has received clinical trial approval from...

Company Drug

Avistone’s Vebreltinib and PLB1004 Receive CDE Breakthrough Therapy Designation for NSCLC

Fineline Cube Apr 17, 2025

China’s Center for Drug Evaluation (CDE) has granted breakthrough therapy designation (BTD) to Beijing Avistone...

Company Deals

Shanghai Pharmaceuticals’ RMB 4.66 Billion M&A Fund Completes AMAC Registration

Fineline Cube Apr 17, 2025

China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) has announced the completion of...

Company Deals

Zhaoke Ophthalmology Signs Distribution Agreements with Thailand’s Interpharma for Myopia and Presbyopia Treatments

Fineline Cube Apr 17, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the signing of three distribution and supply...

Company Drug

Eisai and Biogen Win EU Approval for Leqembi in Early Alzheimer’s Disease

Fineline Cube Apr 17, 2025

Eisai Co., Ltd. (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) jointly announced that they have...

Company

Jiangsu Wuzhong Pharma Faces Forced Delisting After CSRC Investigation

Fineline Cube Apr 17, 2025

China-based Jiangsu Wuzhong Pharmaceutical Group Corp. (SHA: 600200) has disclosed a potential forced delisting from...

Company Drug

Sichuan Biokin’s BL-M09D1 ADC Receives NMPA Clinical Trial Clearance for Solid Tumors

Fineline Cube Apr 17, 2025

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that its antibody-drug conjugate (ADC) BL-M09D1...

Posts pagination

1 … 167 168 169 … 657

Recent updates

  • CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers
  • Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant
  • Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang
  • Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg
  • AstraZeneca Secures FDA Approval for Subcutaneous Saphnelo in Systemic Lupus Erythematosus After Addressing Supplemental Data Request
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Company Drug

Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant

Company Drug

Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang

Company Drug

Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.